Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07597499 · ClinicalTrials.gov registry record · NA
ANCHOR Validation Trial in High-Risk Multidisciplinary Care
A NA study, sponsored by Waymark.
- Completed
- Registry status
- NA
- Development phase
- 240
- Enrollment target
NCT07597499: Completed NA study, sponsored by Waymark.
NCT07597499 is a NA study that has completed, run by Waymark. The registered enrollment target is 240 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07597499, a NA study, has completed, sponsored by Waymark.
- COMPLETED
- Registry status
- NA
- Development phase
- 240 participants
- Enrollment target
Study Summary
This pre-registered, pragmatic, three-arm (1:1:1) patient-level randomized controlled trial with mixed-effects analysis at the encounter level tests two questions in real high-risk multidisciplinary clinical encounters at the Waymark clinically integrated network across three U.S. states (Ohio, Washington, Virginia): (1) does adding ANCHOR - a clinical AI structural verification layer - to a Gemini 3.1 Pro-assisted supervising-physician workflow reduce the rate of clinically meaningful safety failures, compared with the same Gemini 3.1 Pro-assisted workflow without ANCHOR? (2) does the Gemini 3.1 Pro-assisted workflow itself reduce the same safety endpoint compared with unassisted standard care in which the supervising physician writes their own SOAP assessment/plan from a blank template? ANCHOR is a single-call structural verification layer combining a Logical Neural Network (Riegel et al. 2020) certificate, six specialist agents, and concept-decomposed output with PMID citation provenance. ANCHOR is physician-facing only and is used by supervising physicians, not by the multidisciplinary clinical team they oversee. The trial randomizes 240 patients 1:1:1 across the Waymark clinically integrated network over a 12-week active-enrolment window (80 per arm). Eligible patients are adults (age 18+) identified as high-risk by combined claims-based and clinical criteria. Eligible encounters span three integrated Waymark service modalities: high-risk primary care, specialty care coordination, and real-time telemedicine urgent care. The primary endpoint is a per-encounter binary composite: any of (a) failure to mention a do-not-miss diagnosis, (b) under-triage, (c) contraindicated medication recommendation, (d) failure to recommend escalation when clinically warranted; adjudicated by a blinded panel of 3 board-certified physicians with majority-of-three scoring. The primary contrast is Arm 3 (LLM+ANCHOR) versus Arm 2 (LLM with safety prompt), isolating ANCHOR's marginal c
Primary Outcome
Adjudicated binary composite of any of: (a) failure to mention a do-not-miss diagnosis appropriate for the presentation; (b) under-triage (routine/semi-urgent when emergent/urgent appropriate); (c) recommendation of a medication contraindicated by documented allergies/conditions/comorbidities; (d) failure to recommend escalation when clinically warranted. Adjudicated by a blinded panel of 3 board-certified physicians (Internal Medicine, Family Medicine, or Medicine-Pediatrics); final scoring by
Interventions
- BEHAVIORAL Gemini 3.1 Pro with Safety Prompt
- BEHAVIORAL ANCHOR Clinical AI Verification Layer (with Gemini 3.1 Pro)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2026-05-15 |
| Est. Completion | 2026-07-06 |
| Phase | NA |
What the finished NCT07597499 record still lists
NCT07597499 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 2 interventions - of which Gemini 3.1 Pro with Safety Prompt is the first listed.
NCT07597499 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07597499 about?
NCT07597499 is a clinical study titled "ANCHOR Validation Trial in High-Risk Multidisciplinary Care". This pre-registered, pragmatic, three-arm (1:1:1) patient-level randomized controlled trial with mixed-effects analysis at the encounter level tests two questions in real high-risk multidisciplinary clinical encounters at the Waymark clinically integrated network across three U.S. states (Ohio, Wash...
What is the current status of trial NCT07597499?
This trial is currently completed. It is a NA study. The enrollment target is 240 participants. The study started on 2026-05-15. Estimated completion is 2026-07-06.
What interventions are being tested in trial NCT07597499?
The interventions under investigation include: Gemini 3.1 Pro with Safety Prompt (BEHAVIORAL), ANCHOR Clinical AI Verification Layer (with Gemini 3.1 Pro) (BEHAVIORAL).
Who is sponsoring clinical trial NCT07597499?
This trial is sponsored by Waymark, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07597499's enrollment target sits among peer trials
240 440th of 2000 higher than 1,542 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI